This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Salud financiera de hoja de balance de Diffusion Pharmaceuticals

Salud financiera controles de criterios 6/6

Diffusion Pharmaceuticals has a total shareholder equity of $14.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.7M and $1.5M respectively.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$15.00m
Patrimonio	US$14.23m
Total pasivo	US$1.46m
Activos totales	US$15.69m

Actualizaciones recientes sobre salud financiera

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Feb 25

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Nov 12

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Jun 25

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Mar 08

Recent updates

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Aug 12

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Feb 25

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Nov 12

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Jun 25

Diffusion Pharmaceuticals EPS misses by $0.02

May 10

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Mar 08

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Nov 23

Análisis de la situación financiera

Pasivos a corto plazo: DFFN's short term assets ($15.7M) exceed its short term liabilities ($1.5M).

Pasivo a largo plazo: DFFN has no long term liabilities.

Historial y análisis de deuda-patrimonio

Nivel de deuda: DFFN is debt free.

Reducción de la deuda: DFFN had no debt 5 years ago.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: DFFN has sufficient cash runway for more than a year based on its current free cash flow.

Pronóstico de cash runway: DFFN has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 6.4% each year.

This company is no longer active

Salud financiera de hoja de balance de Diffusion Pharmaceuticals

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Diffusion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Diffusion Pharmaceuticals Announces 1-For-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Recent updates

EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN) in a reverse merger transaction.

Diffusion Pharmaceuticals Inc. Announces Resignation of William K. Hornung as CFO

Diffusion Pharmaceuticals Inc. Announces Resignation of Christopher D. Galloway as Chief Medical Officer, Effective March 1, 2023

High number of new and inexperienced directors

LifeSci Special Opportunities Master Fund Ltd Issues an Open Letter to Shareholders of Diffusion Pharmaceuticals Inc

High number of new and inexperienced directors

Diffusion Pharmaceuticals Inc. Announces Resignation of Eric Francois from the Board of Directors and All Committees and Subcommittees

Diffusion Pharmaceuticals Inc., Annual General Meeting, Dec 30, 2022

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger as Chief Regulatory Officer

Diffusion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$100.00

High number of new and inexperienced directors

Diffusion Pharmaceuticals Announces 1-For-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

High number of new and inexperienced directors

High number of new and inexperienced directors

Diffusion Pharmaceuticals Inc. Announces Board Appointments

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

Diffusion Pharmaceuticals Inc. Doses First Participants in Altitude Trial

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Diffusion Pharmaceuticals Inc. Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

Co-Founder & Director John Gainer has left the company

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Diffusion Pharmaceuticals Inc. Reports Final Results from Its Phase 1B Study of Trans Sodium Crocetinate in Hospitalized Covid-19 Patients

Diffusion Pharmaceuticals EPS misses by $0.02

Diffusion Pharmaceuticals Doses First Participants in TCOM Study

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

New 90-day high: US$1.49

New 90-day high: US$1.04

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Price target lowered to US$2.00

New 90-day low: US$0.75

Diffusion Pharmaceuticals Inc. Appoints Christopher D. Galloway as Chief Medical Officer

Diffusion Pharmaceuticals Appoints William Elder as General Counsel and Corporate Secretary

Diffusion Pharmaceuticals Names Dr. Robert Cobuzzi as Chief Executive Officer

New 90-day low - US$0.78

New 90-day high - US$1.47

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera